SCHEMBL2239737

SCHEMBL2239737

O=C(O)C(Cc1ccc(O)cc1)N1C(=O)CC(S(=O)(=O)O)C1=O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.51
KMT2A Q03164 5/20 0.46
MEN1 O00255 3/20 0.46
CYP2D6 P10635 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
ALDH1A1 P00352 2/20 0.46
PKM P14618 1/20 0.46
GAA P10253 1/20 0.40
MME P08473 1/20 0.40
SLC7A5 Q01650 1/20 0.38
HDAC3 O15379 1/20 0.37
HDAC4 P56524 1/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC7 Q8WUI4 1/20 0.37
HDAC2 Q92769 1/20 0.37
HDAC10 Q969S8 1/20 0.37
HDAC11 Q96DB2 1/20 0.37
HDAC8 Q9BY41 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
HDAC9 Q9UKV0 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL230931 0.82 POLB (0.56) POLBKMT2AMEN1CYP2D6TDP1
SCHEMBL859388 0.78 MME (0.46) ALDH1A1PKMMME
SCHEMBL592660 0.76 POLB (0.64) POLBKMT2AMEN1CYP2D6TDP1
SCHEMBL5010177 0.76 ALDH1A1 (0.77) POLBKMT2AMEN1CYP2D6TDP1
SCHEMBL112098 0.76 ALDH1A1 (0.77) POLBKMT2AMEN1CYP2D6TDP1
SCHEMBL9968846 0.74 POLB (0.47) POLBKMT2AMEN1CYP2D6TDP1
SCHEMBL6045666 0.74 MGLL (0.38) TDP1ALDH1A1PKMMMEL3MBTL1
SCHEMBL7199030 0.73 MME (0.45) ALDH1A1MMEHDAC3HDAC4HDAC1
SCHEMBL8818955 0.73 MME (0.42) POLBCYP2D6ALDH1A1MMEHDAC3
SCHEMBL2325576 0.72 MME (0.40) POLBCYP2D6ALDH1A1MMEHDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060035279-A1 Anti-GPE antibodies, their uses and assays for weakly immunogenic molecules NEUREN PHARMACEUTICALS LTD. (NZ) 2006-02-16 US claimed
US-20250367350-A1 CROSSLINKED HYDROGEL COATED MEDICAL GRAFTS COOK BIOTECH INCORPORATED (US) 2025-12-04 US disclosed
US-20250345478-A1 PHOTOCROSSLINKABLE SYNTHETIC POLYMERS Cook Biotech Incoporated (US) 2025-11-13 US disclosed
US-20250325727-A1 PHOTOCURABLE ADHESIVES WITH FERULATED PECTIN COOK BIOTECH INCORPORATED (US) 2025-10-23 US disclosed
US-20250295834-A1 SUBTISSUE IMPLANT MATERIAL COOK BIOTECH INCORPORATED (US) 2025-09-25 US disclosed
EP-3057621-B1 POLYMERIC RADIATION-SOURCES IP LIBERTY VISION CORP (US) 2025-05-14 EP disclosed
US-11957933-B2 Polymeric radiation-sources IP LIBERTY VISION CORPORATION (US) 2024-04-16 US disclosed
US-20230390452-A1 PHOTOCURABLE LIQUID ADHESIVES, AND KITS AND METHODS FOR SAME COOK BIOTECH INCORPORATED (US) 2023-12-07 US disclosed
WO-2023215885-A1 SUBTISSUE IMPLANT MATERIAL COOK BIOTECH INCORPORATED (US) 2023-11-09 WO disclosed
WO-2023215883-A1 PHOTOCROSSLINKABLE SYNTHETIC POLYMERS COOK BIOTECH INCORPORATED (US) 2023-11-09 WO disclosed
US-20110190813-A1 PHOTOACTIVATED CROSSLINKING OF A PROTEIN OR PEPTIDE ELVIN, Christopher M. (AU) 2011-08-04 US disclosed
US-20090111874-A1 Phenyl-containing n-acyl amine and aminoacid derivatives, methods for the production thereof, a pharmaceutical composition and the use thereof OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU PHARMENTERPRISES (RU) 2009-04-30 US disclosed
EP-1876169-A1 PHENYL-CONTAINING N-ACYL AMINE AND AMINOACID DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF, A PHARMACEUTICAL COMPOSITION AND THE USE THEREOF Obschestvo S Ogranichennoi Otvetstennostiyu "Pharmenterprises" (RU) 2008-01-09 EP disclosed
US-20060035279-A1 Anti-GPE antibodies, their uses and assays for weakly immunogenic molecules NEUREN PHARMACEUTICALS LTD. (NZ) 2006-02-16 US disclosed
EP-0454367-B1 Growth hormone releasing factor analogs LILLY CO ELI (US) 1999-11-10 EP disclosed
US-5928667-A Drug delivery device and method for employing the same UNIVERSITY OF MARYLAND (US) 1999-07-27 US disclosed
US-5788959-A Drug delivery device and method for employing the same UNIVERSITY OF MARYLAND, BALTIMORE COUNTY (US) 1998-08-04 US disclosed
WO-1993020107-A1 RECOMBINANT ACTIVE FORMS OF ECEF, PROTEINS THAT ASSOCIATE THEREWITH, AND USES THEREOF BRIGHAM AND WOMEN'S HOSPITAL (US) 1993-10-14 WO disclosed
EP-0454367-A2 Growth hormone releasing factor analogs ELI LILLY AND COMPANY (US) 1991-10-30 EP disclosed
WO-1989002752-A1 METHOD OF DIAGNOSING BLOOD CLOTS USING FIBRIN-BINDING PROTEINS GENENTECH, INC. (US) 1989-04-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11957933-B2 Polymeric radiation-sources RAD54L, RAD18, RAD51 POLB 41/4885KMT2A 3049/4885MEN1 616/4885
US-20090111874-A1 Phenyl-containing n-acyl amine and aminoacid derivatives, methods for the production thereof, a pharmaceutical composition and the use thereof PAH, MAOA, APEH POLB 890/4885KMT2A 3023/4885MEN1 4439/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.